PD-Strat

Title Multi-dimensional stratification of Parkinson's disease patients for personalised interventions.

Coordinator Peter Heutink (German Center for Neurodegenerative Diseases, Germany).

Project partners

🇩🇪 Peter Heutink (German Center for Neurodegenerative Diseases, DE)

🇩🇪 Thomas Gasser (Eberhard-Karls-University Tuebingen, Center of Neurology, Hertie-Institute for Clinical Brain Research, DE)

🇱🇺 Enrico Glaab (University of Luxembourg, Luxembourg Centre for Systems Biomedicine, LU)

🇫🇷 Jean-Christophe Corvol (INSERM UMRS 1127, ICM, Clinical Research Center for Neurosciences, Pitié-Salpêtrière Hospital, FR)

Start date	July 1st, 2018
End date	June 30th, 2021
Funding requested	1.131.000 €
Duration	3 years

Abstract

Parkinsons Disease (PD) is a common disabling, progressive neurological disease. No therapy exists that halts or slows the neurodegenerative process. We hypothesise that this is caused because selection of potential drug targets is rarely based on convincing biological evidence; the disease process begins decades before clinical symptoms and clinical trials on patients are therefore too late and participants have been selected ignoring their underlying disease biology. Therefore, we will develop a disease-mechanism based disease onset and progression prediction model that can be used to generate novel drug targets based on biological evidence with matching precision cohorts for clinical trials that will allow for personalised therapeutic interventions based on genetic and genomic risk profiles and clinical subtypes.

Email peter.heutink@dzne.de